The Angiotensin-Converting-Enzyme-Induced Angioedema

Immunol Allergy Clin North Am. 2017 Feb;37(1):183-200. doi: 10.1016/j.iac.2016.08.011.

Abstract

The bradykinin B2 receptor antagonist icatibant is effective in angiotensin-converting enzyme inhibitor-induced angioedema. The drug is not approved officially for this indication and has to be administered in an emergency situation off-label. Corticosteroids or antihistamines do not seem to work in this condition. The effectiveness of C1-esterase-inhibitor in angiotensin-converting enzyme-induced angioedema must be verified in a double-blind study.

Keywords: ACE inhibitor; Angioedema; Bradykinin; Bradykinin receptors.

Publication types

  • Review

MeSH terms

  • Angioedema / diagnosis*
  • Angioedema / drug therapy
  • Bradykinin / analogs & derivatives
  • Bradykinin / therapeutic use
  • Bradykinin B2 Receptor Antagonists / therapeutic use
  • Diagnosis, Differential
  • Drug-Related Side Effects and Adverse Reactions / diagnosis*
  • Drug-Related Side Effects and Adverse Reactions / drug therapy
  • Emergency Medical Services
  • Epiglottis / immunology
  • Epiglottis / pathology*
  • Humans
  • Off-Label Use
  • Renin / adverse effects
  • Tongue / immunology
  • Tongue / pathology*
  • Urticaria / diagnosis*

Substances

  • Bradykinin B2 Receptor Antagonists
  • icatibant
  • Renin
  • Bradykinin